Intensity Therapeutics Says Cancer Drug Candidate Shows Benefits in Phase 2 Trial

MT Newswires Live2024-12-12

Intensity Therapeutics (INTS) and The Swiss Group for Clinical Cancer Research, or SAKK, said Thursday that cancer drug candidate INT230-6 showed several benefits in a phase 2 trial in multiple tumor types, including triple negative breast cancer.

INT230-6, designed for direct intratumoral injection, leads to local disease control and direct tumor killing as well as has systemic anti-tumor effects, according to a joint statement.

Data from the study showed that INT230-6 has tumor-killing properties at levels greater than 95% in some patients treated with a single dose, as well as "significant" necrosis in tumors bigger than 2 cm in 74% of the patients at the time of surgery, the company and SAKK said.

Intensity and SAKK have also initiated a phase 2 study to assess the clinical activity, safety and tolerability of INT230-6 in patients with early-stage, operable triple negative breast cancer. Recruitment is ongoing, with a target to enroll 54 patients, and seven sites have been activated in Switzerland, they added.

Shares of Intensity Therapeutics fell more than 16% in recent trading.

Price: 1.97, Change: -0.38, Percent Change: -16.17

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2491336877?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2024-12-13 00:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2491336877","market":"sg","top_or_hot":-1,"title":"Intensity Therapeutics Says Cancer Drug Candidate Shows Benefits in Phase 2 Trial","media":"MT Newswires Live","content":"<html><body><p> Intensity <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (INTS) and The Swiss Group for Clinical Cancer Research, or SAKK, said Thursday that cancer drug candidate INT230-6 showed several benefits in a phase 2 trial in multiple tumor types, including triple negative breast cancer.</p><p>INT230-6, designed for direct intratumoral injection, leads to local disease control and direct tumor killing as well as has systemic anti-tumor effects, according to a joint statement.</p><p>Data from the study showed that INT230-6 has tumor-killing properties at levels greater than 95% in some patients treated with a single dose, as well as \"significant\" necrosis in tumors bigger than 2 cm in 74% of the patients at the time of surgery, the company and SAKK said.</p><p>Intensity and SAKK have also initiated a phase 2 study to assess the clinical activity, safety and tolerability of INT230-6 in patients with early-stage, operable triple negative breast cancer. Recruitment is ongoing, with a target to enroll 54 patients, and seven sites have been activated in Switzerland, they added.</p><p>Shares of Intensity Therapeutics fell more than 16% in recent trading.</p><p>Price: 1.97, Change: -0.38, Percent Change: -16.17</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intensity Therapeutics Says Cancer Drug Candidate Shows Benefits in Phase 2 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntensity Therapeutics Says Cancer Drug Candidate Shows Benefits in Phase 2 Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-12-13 00:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Intensity <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (INTS) and The Swiss Group for Clinical Cancer Research, or SAKK, said Thursday that cancer drug candidate INT230-6 showed several benefits in a phase 2 trial in multiple tumor types, including triple negative breast cancer.</p><p>INT230-6, designed for direct intratumoral injection, leads to local disease control and direct tumor killing as well as has systemic anti-tumor effects, according to a joint statement.</p><p>Data from the study showed that INT230-6 has tumor-killing properties at levels greater than 95% in some patients treated with a single dose, as well as \"significant\" necrosis in tumors bigger than 2 cm in 74% of the patients at the time of surgery, the company and SAKK said.</p><p>Intensity and SAKK have also initiated a phase 2 study to assess the clinical activity, safety and tolerability of INT230-6 in patients with early-stage, operable triple negative breast cancer. Recruitment is ongoing, with a target to enroll 54 patients, and seven sites have been activated in Switzerland, they added.</p><p>Shares of Intensity Therapeutics fell more than 16% in recent trading.</p><p>Price: 1.97, Change: -0.38, Percent Change: -16.17</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2491336877","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491336877","pubTimestamp":1734020771,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Intensity Therapeutics  and The Swiss Group for Clinical Cancer Research, or SAKK, said Thursday that cancer drug candidate INT230-6 showed several benefits in a phase 2 trial in multiple tumor types, including triple negative breast cancer.INT230-6, designed for direct intratumoral injection, leads to local disease control and direct tumor killing as well as has systemic anti-tumor effects, according to a joint statement.Data from the study showed that INT230-6 has tumor-killing properties at levels greater than 95% in some patients treated with a single dose, as well as \"significant\" necrosis in tumors bigger than 2 cm in 74% of the patients at the time of surgery, the company and SAKK said.Intensity and SAKK have also initiated a phase 2 study to assess the clinical activity, safety and tolerability of INT230-6 in patients with early-stage, operable triple negative breast cancer. Recruitment is ongoing, with a target to enroll 54 patients, and seven sites have been activated in Swit","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Intensity Therapeutics表示癌症候选药物在2期试验中显示出益处","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INTS":0.9,"LENZ":1},"content_text":"Intensity Therapeutics (INTS) and The Swiss Group for Clinical Cancer Research, or SAKK, said Thursday that cancer drug candidate INT230-6 showed several benefits in a phase 2 trial in multiple tumor types, including triple negative breast cancer.INT230-6, designed for direct intratumoral injection, leads to local disease control and direct tumor killing as well as has systemic anti-tumor effects, according to a joint statement.Data from the study showed that INT230-6 has tumor-killing properties at levels greater than 95% in some patients treated with a single dose, as well as \"significant\" necrosis in tumors bigger than 2 cm in 74% of the patients at the time of surgery, the company and SAKK said.Intensity and SAKK have also initiated a phase 2 study to assess the clinical activity, safety and tolerability of INT230-6 in patients with early-stage, operable triple negative breast cancer. Recruitment is ongoing, with a target to enroll 54 patients, and seven sites have been activated in Switzerland, they added.Shares of Intensity Therapeutics fell more than 16% in recent trading.Price: 1.97, Change: -0.38, Percent Change: -16.17","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2491336877"}